Clinical Trials at DKTK

The effectiveness and safety of new active substances, biomarkers, treatment and diagnostic approaches are first tested in a preclinical phase on cell cultures and animal models. Within the DKTK, special mouse and cell culture systems are being developed that produce results that can be transferred to the human immune system. The effectiveness, dosage and safety of the new treatment and diagnostic concepts are then checked in clinical trials lasting months or years. Promising approaches are then developed further in the laboratory and optimised before going through further clinical control phases. The research focus within the DKTK is on clinical phases I and II. All trials conducted within DKTK can be found in the trial registry of the Clinical Communication Platform. Studies financed within the Joint Funding Program are listed here.

Selection of Current DKTK Studies

Afatinib

AMPLIFY NEOVAC (NOA-21)

ARMANI           

 BliTz     

DACHS

DELPHI

F-MISO-PET      

GliProPh (NOA25)        

HNprädBio       

HypoChoice      

INFORM

INFORM2-NivEnt Trial  

IRINA   

iVacALL

MASTER-Programm     

MEMORI          

N2M2 (NOA-20)           

Oli-P    

PETra   

PORTAF

PriCoTTF          

PRONTOX        

ProtoChoice-Hirn, ProtoChoice-P         

PSMA-11          

PSMAxCD3 Immuntherapie beim Prostatakarzinom (NCT04104607)    

ReKo    

SoraTram         

TOP-ART (NCT PMO-1603)        

TRANSATRA